login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
SKYE BIOSCIENCE INC (SKYE) Stock News
USA
- NASDAQ:SKYE -
US83086J2006
-
Common Stock
1.4
USD
+0.1 (+7.69%)
Last: 11/17/2025, 6:41:48 PM
1.35
USD
-0.05 (-3.57%)
After Hours:
11/17/2025, 6:41:48 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
SKYE Latest News, Press Relases and Analysis
All
Press Releases
7 days ago - By: Skye Bioscience, Inc.
Skye Bioscience Reports Third Quarter 2025 Financial Results and Business Update
10 days ago - By: Investor's Business Daily
- Mentions:
MS
LLY
NVO
VKTX
...
The Weight-Loss Drugs Craze Is Going Strong. But Stock Investors Should Know A Few Things.
12 days ago - By: Skye Bioscience, Inc.
Skye Bioscience Late-Breaking Oral Abstract at ObesityWeek 2025 to Highlight Improvement in Rebound Weight Gain
20 days ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Skye Bioscience, Inc. - SKYE
a month ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Skye Bioscience, Inc. - SKYE
3 months ago - By: Benzinga
- Mentions:
GSAT
PGY
ADV
REAL
...
Earnings Scheduled For August 7, 2025
8 days ago - By: Benzinga
- Mentions:
OGN
TACT
IMDX
QRHC
...
Earnings Scheduled For November 10, 2025
a month ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Skye Bioscience, Inc. - SKYE
a month ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Skye Bioscience, Inc. - SKYE
a month ago - By: Skye Bioscience, Inc.
Skye Bioscience Reports Topline CBeyond™ Phase 2a Data from Nimacimab Monotherapy and Combination Clinical Trial
2 months ago - By: Skye Bioscience, Inc.
Skye Presents Phase 1b Data for its Peripheral CB1-inhibiting Antibody, Nimacimab, at European Association for the Study of Diabetes (EASD) Annual Meeting
2 months ago - By: Skye Bioscience, Inc.
Skye’s CB1 Inhibitor, Nimacimab, Demonstrates Superior Weight Loss and Differentiated Mechanisms from Monlunabant, and Continues to Show Enhanced Combination with Tirzepatide with Durable Post-Treatment Weight Maintenance in DIO Model
3 months ago - By: Skye Bioscience, Inc.
Skye Completes 26-week Treatment Phase in Phase 2a CBeyond™ Study
3 months ago - By: Skye Bioscience, Inc.
Skye Bioscience to Host Virtual KOL Event and Provide Perspectives on Upcoming CBeyond™ Phase 2a Topline Clinical Data Readout
3 months ago - By: Skye Bioscience, Inc.
Skye Bioscience to Participate in Upcoming Investment and Medical Conferences
3 months ago - By: The Motley Fool
Skye (SKYE) Q2 R&D Soars 249% No Revenue
3 months ago - By: Skye Bioscience, Inc.
Skye Bioscience Reports Second Quarter 2025 Financial Results and Business Update
4 months ago - By: Skye Bioscience, Inc.
Skye Bioscience to Announce Second Quarter 2025 Financial Results and Business Update on August 7, 2025
4 months ago - By: Yahoo Finance
- Mentions:
HROW
William Blair Initiates Coverage of Harrow (HROW) With an Outperform Rating
5 months ago - By: Skye Bioscience, Inc.
Skye Bioscience Shares Nimacimab “Anatomy of Progress” Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes Association’s 85th Scientific Sessions
5 months ago - By: Yahoo Finance
- Mentions:
PYPD
Analysts Predict Up to ~590% Spike for These 2 ‘Strong Buy’ Penny Stocks
Please enable JavaScript to continue using this application.